Adverum Biotechnologies Inc (ADVM)
5.82
+0.07
(+1.22%)
USD |
NASDAQ |
Nov 22, 09:44
Adverum Biotechnologies Net Income (Quarterly): -27.13M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -27.13M |
| June 30, 2024 | -18.48M |
| March 31, 2024 | -24.79M |
| December 31, 2023 | -23.71M |
| September 30, 2023 | -32.88M |
| June 30, 2023 | -31.51M |
| March 31, 2023 | -29.06M |
| December 31, 2022 | -32.74M |
| September 30, 2022 | -40.13M |
| June 30, 2022 | -43.76M |
| March 31, 2022 | -37.91M |
| December 31, 2021 | -34.41M |
| September 30, 2021 | -38.36M |
| June 30, 2021 | -44.33M |
| March 31, 2021 | -28.44M |
| December 31, 2020 | -37.63M |
| September 30, 2020 | -27.77M |
| June 30, 2020 | -29.20M |
| March 31, 2020 | -22.91M |
| December 31, 2019 | -18.92M |
| September 30, 2019 | -16.12M |
| June 30, 2019 | -14.95M |
| March 31, 2019 | -14.49M |
| December 31, 2018 | -15.66M |
| Date | Value |
|---|---|
| September 30, 2018 | -20.96M |
| June 30, 2018 | -18.81M |
| March 31, 2018 | -17.20M |
| December 31, 2017 | -14.79M |
| September 30, 2017 | -13.83M |
| June 30, 2017 | -11.43M |
| March 31, 2017 | -16.10M |
| December 31, 2016 | -22.39M |
| September 30, 2016 | -14.30M |
| June 30, 2016 | -61.66M |
| March 31, 2016 | -15.39M |
| December 31, 2015 | -14.09M |
| September 30, 2015 | -14.08M |
| June 30, 2015 | -9.766M |
| March 31, 2015 | -9.509M |
| December 31, 2014 | -10.39M |
| September 30, 2014 | -8.256M |
| June 30, 2014 | -5.094M |
| March 31, 2014 | -1.663M |
| December 31, 2013 | -3.693M |
| September 30, 2013 | -0.813M |
| June 30, 2013 | -0.721M |
| March 31, 2013 | -0.049M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-44.33M
Minimum
Jun 2021
-18.48M
Maximum
Jun 2024
-31.20M
Average
-30.36M
Median
Net Income (Quarterly) Benchmarks
| EyePoint Pharmaceuticals Inc | -29.36M |
| Cassava Sciences Inc | -27.94M |
| Regenxbio Inc | -59.60M |
| Editas Medicine Inc | -62.14M |
| Apellis Pharmaceuticals Inc | -57.44M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.00M |
| Total Expenses (Quarterly) | 30.22M |
| EPS Diluted (Quarterly) | -1.30 |
| Enterprise Value | -33.63M |
| Profit Margin (Quarterly) | -2.71K% |
| Earnings Yield | -103.3% |
| Normalized Earnings Yield | -103.26 |